Kestra Medical Technologies (NASDAQ:KMTS) Insider Alfred Ford, Jr. Sells 5,936 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 5,936 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $22.76, for a total value of $135,103.36. Following the completion of the transaction, the insider directly owned 127,535 shares in the company, valued at approximately $2,902,696.60. This represents a 4.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 5.1%

Shares of NASDAQ:KMTS opened at $23.99 on Tuesday. The company has a market capitalization of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58. The business has a fifty day moving average price of $22.62 and a two-hundred day moving average price of $22.48. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. Kestra Medical Technologies, Ltd. has a 1 year low of $14.10 and a 1 year high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on KMTS shares. Oppenheimer began coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating for the company. The Goldman Sachs Group dropped their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Finally, Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $27.83.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its stake in Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares during the period. Franklin Resources Inc. increased its position in shares of Kestra Medical Technologies by 180.8% during the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after buying an additional 612,343 shares during the period. Millennium Management LLC purchased a new stake in shares of Kestra Medical Technologies in the first quarter worth about $11,036,000. Brown Advisory Inc. boosted its position in shares of Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after acquiring an additional 428,996 shares during the period. Finally, Summit Partners Public Asset Management LLC bought a new position in shares of Kestra Medical Technologies in the fourth quarter valued at approximately $9,282,000.

Trending Headlines about Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.